Tirabrutinib

Name: Tirabrutinib in Primary central nervous system lymphoma: Co-prescribed/Concomitant therapies
Published: 2026-09-14T15:39:06-04:00

Primary central nervous system lymphoma

Manufacturer: Deciphera Pharmaceuticals
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the fiscal year ending March 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Co-prescribed/Concomitant therapies

1 evidence topic · 1 source

Investigational chemotherapy combinations: PROSPECT Part B

“MTR: Methotrexate/ temozolomide/ rituximab” (opens the source at this quote in a new tab)
“R-MPV: Rituximab/ methotrexate/ procarbazine/ vincristine” (opens the source at this quote in a new tab)